目的 分析2018-2019年焦作市第二人民医院黄芪注射液的使用情况，为促进黄芪注射液的临床合理应用提供参考。方法 回顾性调查焦作市第二人民医院2018年1月-2019年6月使用黄芪注射液的病历，记录患者基本情况、药品信息、药品使用情况等进行统计分析。结果 共追踪837份病例，以男性为主，年龄集中在60岁以上的患者，占60.81%。黄芪注射液的使用科室主要为中医科和肿瘤科，构成比分别为28.43%、23.54%。黄芪注射液的用法均为静脉滴注，用量集中10、20 mL/d，共606例，构成比为72.40%。用药疗程主要分布于≤ 7、8~15 d，构成比分别为37.63%、51.49%；与参麦注射液和血栓通注射液的联用最多，构成比分别为35.48%、29.03%。结论 2018-2019年焦作市第二人民医院黄芪注射液的应用基本合理，临床使用中存在不辨证论治的情况，为提高中药的临床疗效，避免不良反应，在使用过程中应辨证论治，提升其临床应用的合理性。

Objective To analyze the clinical use of Huangqi Injection in the Second People's Hospital of Jiaozuo from 2018 to 2019, and to provide reference for promoting the rational clinical application of Huangqi Injection. Methods Medical records using Huangqi Injection in the Second People's Hospital of Jiaozuo from 2018 to 2019 were retrospectively analyzed, recording the basic situation of patients, drug information, and drug use. Results 837 Cases were tracked, and most of them were male. The ages of moat patients were above 60 years old, accounting for 60.81%. The main departments using Huangqi Injection were Department of TCM and Department of oncology, accounting for 28.43% and 23.54%. Huangqi Injection was intravenous drip, and the dose was 10 and 20 mL/d, and there were 606 cases, accounting for 72.40%.The treatment course was mainly distributed in ≤ 7 and 8-15 d, with the composition ratio of 37.63% and 51.49%. The combination of Shenmai Injection and Xueshuantong Injection was more, accounting for 35.48% and 29.03%. Conclusion The application of Huangqi Injection in the Second People's Hospital of Jiaozuo from 2018 to 2019 is basically reasonable. There are cases of non-dialectical treatment in clinical use, in order to improve the clinical curative effect of traditional Chinese medicine, and avoid adverse reactions. Therefore, syndrome differentiation should be treated in the process of use to improve the rationality of its clinical application.

R972